The drug stability, oxidative and hydrolyzed drugs are protected by light, oxygen, heat and certain factors after being encapsulated by cyclodextrin, so that the drug efficacy and shelf life are prolonged. The inclusion complex is formed with beta-cyclodextrin and vitamin D2. The change of VD2 content in the clathrate was determined under light, high temperature and high humidity conditions. After two years, the VD2 in the clathrate remained above 85%, while the unencapsulated VD2 was less than 22%. The cyclodextrin inclusion complex solved the problem of stable content of VD2.

The solubility and dissolution rate of the drug are increased. The cyclodextrin inclusion compound is equivalent to a molecular capsule, and the drug molecule is separated and dispersed in the oligosaccharide skeleton. As the drug molecule interacts with the hydroxyl groups on the cyclodextrin and the crystallinity of the drug in the clathrate decreases, the solubility and dissolution rate of the drug increases. It masks the bad odor of the drug and reduces the irritation, improves the bioavailability, improves the dosage form, and improves the stability of the drug during the preparation process. Volatile drugs are made into cyclodextrin inclusion complexes, in addition to reducing volatilization, there is also a sustained release effect. Ciprofloxacin is a fluoroquinolone drug and is a commonly used drug in veterinary clinics in recent years. However, due to the short half-life and strong irritancy, repeated injections are needed, which affects its widespread use. The inclusion of ciprofloxacin and beta-cyclodextrin can delay the release of drug for 72 hours.